With a focus on pharmacogenomics testing, proposed legislation would boost public demand for precision medicine treatments and build better electronic infrastructure to support precision medicine.
“While other teams have documented that this gene can be suppressed in cells in culture, this is the first time this type of antisense oligonucleotide treatment for C9ORF72 ALS has been demonstrated in a person with ALS.”
Multi-center studies underway to enhance ability to personalize treatments for people with severe asthma.
Applying precision medicine principles, a four-year study at Indiana University School of Medicine advances diagnostics and therapeutics for depression and bipolar disorder.
Research will continue toward the value and medical necessity of both WES and WGS where results directly influence medical management and clinical outcomes. As a result, reimbursement for the uses of these testing methods may be changing as more about their roles is learned.
Because of the increased number of risk adjustment programs, improved diagnosis and treatment of chronic kidney disease (CKD) could trigger substantial financial benefit. This research maps a path for physicians and health systems to better utilize existing medications for their patients with CKD.
The nuclear medicine hub in Indiana will generate research, discovery, and evidence of the safety and efficacy of radiopharmaceuticals at a time when the FDA recently has approved two molecular imaging drugs for prostate cancer.
A San Francisco-based otolaryngology practice recently implemented genetic-based treatment offerings. Lessons learned here could be used to guide other practice or hospital leaders that are developing a precision medicine strategy.
James Glazier, PhD, is a professor of intelligent systems at the Indiana Luddy School of Informatics, Computing, and Engineering. Dr. Glazier is uncovering new potential in the concept of “digital twins.” His findings were published in Science. What are digital twins and why are they becoming important for precision medicine?
German-based diagnostics company identifies biomarkers that could help reduce sepsis costs, suggests basing a precision medicine initiative in the hospital ICU.